Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 954-965

  Bekker, Linda Gail ^c   Haslett, Patrick ^a   Maartens, Gary ^c   Steyn, Lafras ^c   Kaplan, Gilla ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CELGENE CORPORATION   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; THALIDOMIDE;

ANTIGEN SPECIFICITY; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUBERCULOSIS; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADJUVANTS, IMMUNOLOGIC; ADULT; BODY MASS INDEX; CD40 LIGAND; CYTOKINES; FEMALE; HIV-1; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, CYTOKINE; T-LYMPHOCYTES; THALIDOMIDE; TUBERCULOSIS; VIRUS REPLICATION;

EID: 0034076201     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315328     Document Type: Article

References (43)

1. 1. I. Donald PR. The epidemiology of tuberculosis in South Africa. Novartis Found Symp 1998;217:24-35.
2. 2. Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis 1998;2:919-25.
3. 3. Wilkinson D, Davies GR. The increasing burden of tuberculosis in rural South Africa-impact of the HIV epidemic. S Afr Med J 1997;87:447-50.
4. 4. Wilkinson D, Pillay M, Crump J, Lombard C, Davies GR, Sturm AW. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural Africa. Trop Med Int Health 1997;2:747-53.
5. 5. Wood R, Hudson C. HIV-related tuberculosis. S Afr Med J 1997;87:1018-9.
6. 6. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-8.
7. 7. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997;155:996-1003.
8. 8. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-75.
9. 9. Stanley S, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type I. N Engl J Med 1996;334:1222-30.
10. 10. Kinter AL, Poli, G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995;154: 2448-59.
11. 11. Margolick JB, Volkman DJ, Folks TM, Fauci AS. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J Immunol 1987;138:1719-23.
12. 12. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4.
13. 13. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-57.
14. 14. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2336-40.
15. + T cells using a combination of cytokines. J Exp Med 1998;188:83-91 (erratum: J Exp Med 1998;188:614).
16. 16. Bekker LG, Maartens G, Steyn L, Kaplan G. Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998; 178:580-4.
17. 17. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
18. 18. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
19. + subset. J Exp Med 1998;187:1885-92.
20. 20. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-α. J Immunol 1999;163:380-96.
21. 21. Haslett PAJ, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-79.
22. 22. Noormohamed FH, Youle MS, Higgs CJ, et al. Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res Hum Retroviruses 1999;15:1047-52.
23. 23. Haslett PAJ, Tramontana J, Burroughs M, Hempstead M, Kaplan G. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;24:1223-7.
24. 24. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations [corrected]. MMWR Morb Mortal Wkly Rep 1997;46(RR-15): 1-10 (erratum: 1997;46:880).
25. 25. English D, Andersen BR. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 1974;5:249-52.
26. 26. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996;196:121-35.
27. 27. Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol 1996;93:943-9.
28. 28. Chain BM, Kay PM, Feldmann M. The cellular pathway of antigen presentation: biochemical and functional analysis of antigen processing in dendritic cells and macrophages. Immunology 1986;58:271-6.
29. 29. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.
30. 30. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7: 445-80.
31. 31. Moller DR, Wysocka M, Greenlea BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-61.
32. 32. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998;17: 269-78.
33. 33. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor deficient patients. Science 1998;280: 1435-8.
34. 34. Chehimi J, Starr SE, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994;179: 1361-6.
35. 35. Chougnet C, Thomas E, Landay AL, et al. CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. Eur J Immunol 1998;28:646-56.
36. 36. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-spedfie cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262: 1721-4.
37. 37. Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Storkus WJ. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol 1999;162:3070-8.
38. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest 1998;102:2072-81.
39. 39. Ryffel B. Unanticipated human toxicology of recombinant proteins. Arch Toxicol Suppl 1996;18:333-41.
40. 40. Gori A, Franzetti F, Marchetti G, et al. Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection. Clin Infect Dis 1998;26:184-5.
41. + T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995;92:10985-9.
42. 42. Stenger S, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999;2:89-93.
43. 43. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.